Biomea Fusion
Yahoo Finance • 2 days ago
Biomea Fusion announces pricing of public offering of securities
* Biomea Fusion (NASDAQ:BMEA [https://seekingalpha.com/symbol/BMEA]) announced the pricing of its public offering for gross proceeds of $25 million. * The offer consists of 11.19M shares of its common stock and accompanying warrants to... Full story
Yahoo Finance • 2 days ago
Biomea Fusion Announces Pricing of Public Offering of Securities
SAN CARLOS, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering cons... Full story
Yahoo Finance • 3 days ago
Biomea Fusion rises after results from type 2 diabetes drug
[Teenager With Type 1 Diabetes Takes at Home Test] kyotokushige Biomea Fusion (NASDAQ:BMEA [https://seekingalpha.com/symbol/BMEA]) shares rose after reporting positive results from its mid-stage study testing icovamenib in individuals wit... Full story
Yahoo Finance • 3 days ago
Biomea Fusion Announces Proposed Public Offering of Securities
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its co... Full story
Yahoo Finance • 3 days ago
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, with a 1.8% placebo a... Full story
Yahoo Finance • 8 days ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation c... Full story
Yahoo Finance • last month
American International Group (AIG) Shares Cross Below 200 DMA
In trading on Friday, shares of American International Group Inc (Symbol: AIG) crossed below their 200 day moving average of $57.73, changing hands as low as $57.67 per share. American International Group Inc shares are currently trading... Full story
Yahoo Finance • last month
Five Below upgraded, Bill downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Telsey Advisory upgraded Five Below(FIVE... Full story
Yahoo Finance • 4 months ago
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide... Full story
Yahoo Finance • 4 months ago
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025;... Full story
Yahoo Finance • 4 months ago
Meta, Peloton and Hasbro rise premarket; AstraZeneca falls
Investing.com -- U.S. stock futures edged higher Wednesday, as traders digested the ongoing conflict in the Middle East as well as the conclusion of the latest Federal Reserve meeting. Here are some of the biggest premarket U.S. stock mov... Full story
Yahoo Finance • 4 months ago
Biggest stock movers Wednesday: UBS, BTDR, and more
[Mixed group of millennial aged friends discuss investing and cryptocurrency trading] Trevor Williams Stock futures edged higher early Wednesday as investors awaited the Federal Reserve’s interest rate decision due later in the day. Here... Full story
Yahoo Finance • 4 months ago
Biomea Fusion launches public offering of common stock and warrants
REDWOOD CITY, Calif. - Biomea Fusion, Inc. (NASDAQ:BMEA), a clinical-stage diabetes and obesity company with a market capitalization of $109 million, announced Tuesday it has commenced an underwritten public offering of common stock shares... Full story
Yahoo Finance • 4 months ago
Biomea Fusion launches public offering of stock and warrants; shares down 23%
* Biomea Fusion (NASDAQ:BMEA [https://seekingalpha.com/symbol/BMEA]) has commenced an underwritten public offering of common stock, pre-funded warrants, and accompanying stock warrants. * Certain investors may receive pre-funded warran... Full story
Yahoo Finance • 4 months ago
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the o... Full story
Yahoo Finance • 5 months ago
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently un... Full story
Yahoo Finance • 6 months ago
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation co... Full story
Yahoo Finance • 6 months ago
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamen... Full story
Yahoo Finance • 7 months ago
Biomea Fusion Announces Leadership Transition
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” or... Full story
Yahoo Finance • 7 months ago
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of icovamenib Strong correlation between C-peptide... Full story
